Page 20«..10..19202122..3040..»

Archive for the ‘Arthritis’ Category

AbbVie’s Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original – The Motley Fool

Tuesday, June 16th, 2020

AbbVie (NYSE:ABBV) has a solution for the loss of patent protection on its blockbuster drug Humira: ABBV-3373, a souped-up version of the monoclonal antibody that's quite literally Humira on steroids; it's Humira, an antibody that targets tumor necrosis factor (TNF), connected to a glucocorticoid receptor modulator (GRM) steroid.

In a phase 2a clinical trial, ABBV-3373 reduced the Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) -- a measurement of the severity of rheumatoid arthritis disease -- by 2.65 points, compared to a decline of 2.13 points for patients who were given Humira in other clinical trials. The phase 2a study also had some patients on Humira, and when data from those patients was combined with the historical Humira data, Abbvie calculated that there was a 90% chance that ABBV-3373 was associated with a greater improvement in DAS28-CRP than Humira.

Image source: Getty Images.

Antibody-drug conjugates have been used for decades to treat cancer by using an antibody to target a toxic payload to tumor cells. But AbbVie is using the technology to target a molecule -- the GRM steroid that is anti-inflammatory -- to activated immune cells while still blocking the pro-inflammatory TNF protein. By specifically targeting activated immune cells, the drugmaker hopes to dampen the systemic side effects seen with glucocorticoid steroids.

A few other companies are developing antibody-drug conjugates where the additions aren't the traditional toxic payload. Privately held Bolt Biotherapeutics and Silverback Therapeutics, for instance, are using antibodies to target tumor cells and attaching molecules that can stimulate immune cells to attack the cancerous ones. And Avidity Biosciences, which has filed to go public under the ticker RNA, is attaching oligonucleotides to antibodies in order to target them to specific cells in the body.

Here is the original post:
AbbVie's Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original - The Motley Fool

Read More...

Psoriatic Arthritis Therapeutics Market Analysis Of Global Trends, Demand And Competition 2020-2028 – 3rd Watch News

Tuesday, June 16th, 2020

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Psoriatic Arthritis Therapeutics market.

Trusted Business Insights presents an updated and Latest Study on Psoriatic Arthritis Therapeutics Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Psoriatic Arthritis Therapeutics market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Global Psoriatic Arthritis Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global Psoriatic Arthritis Therapeutics market report has been segmented on the basis of drug, diseases type, and region.

Request Covid 19 Impact

Global Psoriatic Arthritis Therapeutics Market: Overview

Psoriatic arthritis (PsA) is a type of chronic disease, characterized by inflammation in the joints and skin. This disease is progressive category of diseases that may worsening over time. If left untreated, this psoriatic arthritis may lead to joint damage permanently. It is characterized by potential involvement of diverse tissues, including, enthesitis, peripheral and axial joints, skin & nail disease, and dactylitis. The treatment of PsA includes the use of a variety of interventions that act as an agent for the treatment of patients with other forms of inflammatory arthritis, such as rheumatoid arthritis (RA), spondyloarthritis and others.

Global Psoriatic Arthritis Therapeutics Market: Dynamics

Increasing number of cases of psoriatic arthritis especially in elderly population is a key factor expected to drive the growth of the global market over the forecast period. In addition, rising awareness about psoriatic arthritis treatment among the healthcare professionals and increasing elderly population. The above mentioned are some of the other factors expected to drive growth revenue of the global market. However, high cost of the drugs and treatment, entry of biosimilar drug in the market, and lack of standardization tools for diagnosis and treatment. These are some of the major factors expected to hamper growth of the target market to a certain extent.

Global Psoriatic Arthritis Therapeutics Market: Segment Analysis

Among the drug type segments, Nonsteroidal anti-inflammatory drug is estimated to account for majority of revenue share in the global market. This is due to, rising prescribing of NSAID drugs for patients, in order to pain and morning stiffness, controlling swelling, and to improve range of motion to joints.

Among the diseases type segments, symmetric psoriatic arthritis is estimated to hold highest revenue and register highest CAGR over the forecast period, due to increasing number of cases of affecting several joints in pairs on both sides of your body. It may damage joints over time, that can lead to limited movement and function of body.

Global Psoriatic Arthritis Therapeutics Market: Trends

The established players are adopting various growth strategies such as partnership, collaboration, mergers, new product launch etc., in order to cater the growing demand for Psoriatic Arthritis Therapeutics globally. In addition, the prominent players are collaborating with local player in order to form string value and supply chain. The aforementioned are some of the current key trend witnessed in the target market.

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

In 2019, the markets in North America estimated to account for highest market revenue share in the target market over the forecast period. This is primarily attributed to, increasing incidences of psoriatic arthritis. According to RheumatoidArthritis.org, which is a non-profit team of healthcare professionals around 85% of individuals living with psoriatic arthritis in US. The markets in Asia Pacific accounted for highest CAGR over the forecast period, owing to increasing prevalence and incidences in the temperate zones in the region, and growing healthcare expenditure. In addition, higher demand and increased rate of adoption of biologic drugs in countries such as Australia & New Zealand, are projected to drive the psoriatic arthritis therapeutics market in Asia Pacific region.

Global Psoriatic Arthritis Therapeutics Market Segmentation:

Segmentation by drug:

Nonsteroidal anti-inflammatory drug (NSAID)Disease-modifying antirheumatic drug (DMARD)Biologic drugEnzyme inhibitor

Segmentation by diseases type:

Asymmetric Psoriatic ArthritisSymmetric Psoriatic ArthritisDistal Interphalangeal Predominant (Dip) Psoriatic ArthritisSpondylitisArthritis Mutilans

Quick Read Table of Contents of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

View original post here:
Psoriatic Arthritis Therapeutics Market Analysis Of Global Trends, Demand And Competition 2020-2028 - 3rd Watch News

Read More...

Arthritis drugs used in new coronavirus treatment trial – The Irish News

Tuesday, June 16th, 2020

Jess Glass, Press Association

10 June, 2020 16:06

Drugs used to treat conditions including rheumatoid arthritis will be tested as potential treatments in a Covid-19 trial.

Researchers at the University of Birmingham announced on Wednesday that four drugs will be used as part of their Catalyst trial into therapeutics for patients with the virus.

The trial will use drugs that are on the market or are in late stages of clinical trials to treat hospitalised patients with Covid-19, in the hope they can prevent them from needing intensive care.

The first drug in the research is Namilumab, produced by the Oxford-based Izana Bioscience, which is in late-stage trials for use for rheumatoid arthritis and the inflammatory disease ankylosing spondylitis.

READ MORE:Coronavirus: Tougher border controls 'more effective if introduced earlier', MPs told

The drug targets substances called cytokines which are naturally released by immune cells but can cause damage during an over-reaction of the immune system known as a cytokine storm.

These substances are believed to be a key factor in the excessive and potentially dangerous lung inflammation seen in some Covid-19 patients.

The second drug is Infliximab, developed by Slough-based Celltrion Healthcare UK, and is an anti-tumour necrosis therapy.

It is currently used to treat inflammatory and autoimmune conditions including rheumatoid arthritis and irritable bowel syndrome.

The other two drugs to be used in the trial will be announced at a later date.

Researchers hope that by targeting some of the most serious symptoms of Covid-19, the severity of the disease could be reduced leading to a fall in deaths.

Researchers at the University of Birmingham are testing four different drugs which could be used to treat coronavirus

Dr Ben Fisher, co-clinical investigator of the Catalyst trial, said: "Emerging evidence is demonstrating a critical role for anti-inflammatory drugs in the cytokine storm associated with severe Covid-19 infection.

"In the Catalyst study, we hope to show with a single dose of these kinds of drugs in hospitalised patients that we are able to delay or prevent the rapid deterioration into intensive care and requirement for invasive ventilation in this critical patient group."

Up to 40 Covid-19 patients will be recruited to each part of the trial and will be randomly selected to either receive standard treatment alone or treatment with the addition of one of the four drugs.

The trial has been designed by the inflammation - advanced and cell therapy trials Team at the University of Birmingham's Cancer Research UK clinical trials unit.

In addition to the team at the university, the trial is being conducted with University Hospitals Birmingham NHS Foundation Trust, as well as teams from Oxford University and University College London.

Recruitment for patients has started in Oxford and Birmingham.

If a drug is found to be successful, the trial will be expanded for further testing on a national level.

Read the original:
Arthritis drugs used in new coronavirus treatment trial - The Irish News

Read More...

GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel – PRNewswire

Tuesday, June 16th, 2020

WARREN, N.J., June 11, 2020 /PRNewswire/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced that Voltaren Arthritis Pain Gel (diclofenac sodium topical gel, 1% (NSAID) arthritis pain reliever) recently became available over-the-counter (OTC) online and in stores nationwide, providing the over 30 million1 osteoarthritis patients across the country broader access to a leading pain relief option.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8731451-gsk-partners-with-paula-abdul-to-launch-voltaren-arthritis-pain-gel/

To launch the OTC offering, Voltaren is teaming up with music superstar Paula Abdul, who uses Voltaren for her arthritis pain. Staying active is important for arthritis patients everywhere, and together, Voltaren and Paula Abdul will inspire people to "rediscover the joy of movement".

"I'm excited to partner with Voltaren Arthritis Pain Gel to share my personal journey with arthritis and success using Voltaren," Paula said. "I've put my joints through a lot over the years. Dancing, jumping, flipping it's my heart and soul, but I've been pushing my joints to the limit for decades as a result. When I was diagnosed with arthritis, my doctor prescribed Voltaren which made a huge difference in relieving my pain and helping me move with ease. I am so excited it's now available OTC at stores nationwide."

Joint pain due to arthritis symptoms is a daily reality for millions of people in the United States, and with many people across the country staying at home more often, finding arthritis pain relief is more important than ever. In a recent study of 1,000 U.S. adults aged 35+ suffering from joint pain* conducted by Voltaren in partnership with Wakefield Research, 82 percent of respondents said their physical activity has decreased as a result of more time at home, and 92 percent of respondents report that their joint pain is the same or more severe during this time.

"Stay-at-home orders led to a unique set of challenges for those with arthritis," said Jissan Cherian, Director,U.S. OTC Marketing at GSK Consumer Healthcare. "Now, more than ever, we need to offer solutions that help ease the challenge of joint pain and inspire arthritis patients to rediscover the joy of movement, even as we adapt to changing routines and a new way of life."

Additional results from the survey revealed:

Voltaren Gel, a doctor-prescribed arthritis treatment in the U.S. for over 10 years with a proven safety profile, was approved by the Food and Drug Administration (FDA) as an OTC treatment in February, making it the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States. As an alternative to pills, Voltaren treats joint pain by delivering medicine at the source, and is absorbed through the skin and not through the stomach like most oral medicines. Voltaren is applied directly to the site of pain, delivering powerful arthritis pain relief. It is indicated for the treatment of arthritis pain in the hand, wrist, elbow, foot, ankle or knee. To date, millions of patients around the world have relied on Voltaren as a powerful, well-tolerated and convenient therapeutic alternative for treating arthritis pain.

"As the world leader in pain relief, we have seen how Voltaren has helped people with osteoarthritis treat their pain and improve their quality of life" Cherian said. "The OTC availability of Voltaren Arthritis Pain helps to provide greater access to an effective topical treatment option for joint pain patients, so more people with osteoarthritis pain can find relief."

Voltaren Arthritis Pain Gel is now available online and at most major retailers nationwide.

About Voltaren Arthritis Pain GelThe active ingredient in Voltaren Arthritis Pain Gel, diclofenac sodium, is an effective medicine that is clinically proven to relieve joint pain due to arthritis. Voltaren penetrates throughthe skin at the application site to deliver arthritis pain relief. Voltaren offers consumers who suffer from OA a well-tolerated alternative to oral analgesics. For more information, visithttps://www.VoltarenGel.com/.

About osteoarthritis Osteoarthritis (OA) is the most common form of arthritis. OA occurs when the cartilage between joints begins to break down and wear away, resulting in joint pain and stiffness. OA occurs more frequently with age, and the pain can gradually worsen over time. The most common symptoms associated with OA include joint pain, stiffness, and decreased range of motion.

GSK's commitment to pain reliefWe are the world leader in pain relief. With a portfolio of (systemic and topical) products to relieve pain, our range brings comfort and ease to millions. World-leading brands including Advil, Panadol and Voltaren; and beloved local brands like Excedrin in the US and Fenbid in China help people manage their symptoms so they can enjoy life to the fullest.

Important safety information about Voltaren Arthritis Pain Before using the product, consumers should read the Voltaren Arthritis Pain Gel Drug Facts Label.

* Methodological NotesThe GSK Voltaren Survey was conducted by Wakefield Research (www.wakefieldresearch.com) between May 7th and May 15th, 2020, among 1,000 US adults ages 35+ suffering from joint pain, plus an additional oversample of 500 joint pain sufferers in each of three states: Georgia, Oklahoma, Louisiana, using an email invitation and an online survey.

Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percentage points from the result that would be obtained if the interviews had been conducted with all persons in the universe represented by the sample.

About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit http://www.gsk.com.

About GSK Consumer Healthcare We are the world's largest Consumer Healthcare company following our new joint venture with Pfizer Consumer Healthcare. We develop and market a portfolio of consumer-preferred and expert-recommended brands including Sensodyne, parodontax, Poligrip, Advil, Centrum and Theraflu.

Media Inquiries:

GSK Consumer Healthcare

Caitlin Kormann

+1 617 448 0557

(Warren)

Edelman

Jessica Moschella

+1 201 953 1547

(New York City)

1https://www.cdc.gov/arthritis/basics/osteoarthritis.htm

SOURCE GSK Consumer Healthcare

http://www.gsk.com

See the article here:
GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel - PRNewswire

Read More...

Rheumatoid Arthritis and Lupus Treatments Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of…

Tuesday, June 16th, 2020

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis and Lupus Treatments Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis and Lupus Treatments, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=275894&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis and Lupus Treatments manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis and Lupus Treatments Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis and Lupus Treatments market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis and Lupus Treatments market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis and Lupus Treatments Market, By Product

Rheumatoid Arthritis and Lupus Treatments Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275894&utm_source=COD&utm_medium=888

Rheumatoid Arthritis and Lupus Treatments Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis and Lupus Treatments market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis and Lupus Treatments Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis and Lupus Treatments Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis and Lupus Treatments Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis and Lupus Treatments Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis and Lupus Treatments Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis and Lupus Treatments Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis and Lupus Treatments Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=275894&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Plastic Strip Doors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Plastic Tube Filler and Sealer Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Plastics for Passenger Cars Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the rest here:
Rheumatoid Arthritis and Lupus Treatments Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of...

Read More...

Global Psoriatic Arthritis Drug Market with (Covid-19) Impact Analysis: Growth, Latest Trend Analysis and Forecast 2025 – Cole of Duty

Tuesday, June 16th, 2020

Researchstore.biz has published an exclusive report named Global Psoriatic Arthritis Drug Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which consists of overall market scenario with prevalent and future growth prospects. The report delivers the analytical elaboration and other industry-linked information in an aim to supply specific and reliable analysis on the global Psoriatic Arthritis Drug market. The report focuses on market dynamics, growth-driving factors, restraints, and limitations this market is currently facing and is expected to face in the coming years (2020-2025). The report is further divided by company, by country, and by application/types for the competitive landscape analysis. It estimates production chain, manufacturing capacity, sales volume, and revenue.

The report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive landscape, sales analysis, the impact of domestic and global market players. It contains advanced information associated with the global Psoriatic Arthritis Drug market status, trends analysis, segment, and forecasts from 2020-2025. It explains market scenarios, comparative pricing between major players, cost, and profit of the specified market regions.

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Psoriatic Arthritis Drug market.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/29246

Key Players Analysis:

The report analyzes the top manufacturers, exporters, and retailers (if applicable) around the world concerning their company profile, product portfolio, capacity, price, cost, and revenue. For competitor segment, the report covers the following global Psoriatic Arthritis Drug market key players and some other small players: Abbvie, Pfizer, Janssen, Amgen, Celgene, Eli-lilly

In market segmentation by types, the report covers: TNF Inhibitors, PDE4 Inhibitors, Interleukin Blockers, Other,

In market segmentation by applications, the report covers the following uses: Mild Psoriatic Arthritis, Moderate Psoriatic Arthritis, Severe Psoriatic Arthritis,

Regionally, this report focuses on several key regions: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Moreover, the report exhaustively investigates business opportunities, market scope, threats, and barriers. The report aims to help companies in strategizing their decisions in a better way and finally attains their business goals. The research answers important business questions like how the global Psoriatic Arthritis Drug market will perform in the existing market scenario. It also presents the potential industry supply, market demand, market value, market competition, key market players, and the industry estimate from 2020-2025.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-psoriatic-arthritis-drug-market-29246

Important Key Questions Answered In The Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Read more:
Global Psoriatic Arthritis Drug Market with (Covid-19) Impact Analysis: Growth, Latest Trend Analysis and Forecast 2025 - Cole of Duty

Read More...

Rheumatoid Arthritis Drugs Manufacturers Profiles, Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 -…

Tuesday, June 16th, 2020

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis Drugs Manufacturers Profiles, Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis Drugs Manufacturers Profiles,, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=231874&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis Drugs Manufacturers Profiles, manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis Drugs Manufacturers Profiles, Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis Drugs Manufacturers Profiles, market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis Drugs Manufacturers Profiles, market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis Drugs Manufacturers Profiles, Market, By Product

Rheumatoid Arthritis Drugs Manufacturers Profiles, Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=231874&utm_source=COD&utm_medium=888

Rheumatoid Arthritis Drugs Manufacturers Profiles, Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis Drugs Manufacturers Profiles, market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis Drugs Manufacturers Profiles, Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis Drugs Manufacturers Profiles, Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis Drugs Manufacturers Profiles, Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis Drugs Manufacturers Profiles, Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis Drugs Manufacturers Profiles, Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis Drugs Manufacturers Profiles, Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis Drugs Manufacturers Profiles, Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=231874&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Healthcare IT Solutions Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Healthcare Supply Chain Management Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Clinical Trial Management System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Rheumatoid Arthritis Drugs Manufacturers Profiles, Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 -...

Read More...

‘Ive dislocated my hip and the pain is so bad Ive thought about taking my own life’ – Telegraph.co.uk

Tuesday, June 16th, 2020

When lockdown came into force, I was anxious. Im at high risk of getting a severe form of Covid-19, since I have rheumatoid arthritis (RA) and swallow an army of immunosuppressant drugs every day. I live in London with my boy Mr Darcy, my handsome Lucas Terrier but my parents felt it was safer for me to be with them, in Hampshire. We get on well. Ever since I was diagnosed with RA aged 18 (I am now 46) we have been through so much adversity together that we have become a team.

It was March 25, another day, much the same as the day before, I thought, until it happened. I was walking Darcy on Stockbridge Down when I heard my left hip make a crunching sound. Over the past twenty-eight years, I have had multiple joint replacement operations, and two of these have been hip replacements and revision surgery on this particular left-hand side. With every step I made, I winced at this crunching sound like a tyre going over gravel. Unbeknownst to me I had broken my pelvis and fractured my hip. Essentially my replacement joint had shattered.

With Mr Darcy alongside, oblivious to my fear, I staggered a quarter of a mile back to my car. In shock, I drove home. With hindsight, I dont know how I managed to get home.

The following day, an x-ray was taken, confirming a catastrophic hip replacement failure. I was advised not to walk at all (not that I could), to use a wheelchair and if I had to move around the house, to get around on a gutter frame. No stairs. It was frightening going from a generally active person I love my swimming and dog walks to someone trapped in a body, unable to move for fear of doing further damage. To add to the trauma, no operation could be done because of Covid-19.

Ordinarily, I would have had surgery immediately. Yet we were nowhere near the peak of the virus. It was a question of waiting, the surgeon told me. Reluctantly, I could see his point; I understood an operation wasnt possible. I understood the risk of getting the virus too and feared passing it on to my parents. We were stuck.

Almost three months on and I can honestly say the last twelve weeks have been the most gruelling weeks I have ever endured. Mentally I have been down some dark paths: paths of wanting to give up simply take my own life and be done with further pain and surgery. Why bother living like this? I have been down paths of reliving the trauma of previous surgery dreading the operation to come, yet knowing that unless I have it I wont be able to walk my Darcy again, something I so desperately miss.

Originally posted here:
'Ive dislocated my hip and the pain is so bad Ive thought about taking my own life' - Telegraph.co.uk

Read More...

Rheumatoid Arthritis Drugs Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Tuesday, June 16th, 2020

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis Drugs Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis Drugs, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=212614&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis Drugs manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis Drugs Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis Drugs market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis Drugs market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis Drugs Market, By Product

Rheumatoid Arthritis Drugs Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=212614&utm_source=COD&utm_medium=888

Rheumatoid Arthritis Drugs Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis Drugs market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis Drugs Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis Drugs Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis Drugs Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis Drugs Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis Drugs Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis Drugs Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis Drugs Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=212614&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Wind Automation Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wind Power Coatings Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wind Power Paint Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Continued here:
Rheumatoid Arthritis Drugs Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Read More...

Health News Roundup: Trial of rheumatoid arthritis drug in COVID-19 patients; new Ebola outbreak in Congo and more – Devdiscourse

Tuesday, June 16th, 2020

Following is a summary of current health news briefs.

Explainer: Europe steps up tech battle vs. coronavirus with German app

Germany on Tuesday becomes the latest European country to launch a smartphone app that seeks to break the chain of coronavirus infection by tracking encounters between people and issuing a warning should one of them test positive. A growing number of countries in the region have opted to use Bluetooth short-range radio to measure the risk of exposure, after concluding that tracking people's movements using location data would be intrusive.

Norway to halt COVID-19 track and trace app on data protection concerns

Norway will halt its COVID-19 track and trace app and delete all data collected so far after criticism from the Norwegian Data Protection Authority, the Norwegian Institute of Public Health (NIPH) said on Monday. The app was introduced by some Norwegian authorities to limit the transmission of the coronavirus.

Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients

Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19. The trial is one of several efforts by the U.S. drugmaker to help combat the coronavirus pandemic, which has killed more than 400,000 people globally, according to a Reuters tally.

Up to 17 infected, 11 dead in new Ebola outbreak in Congo

The Democratic Republic of Congo has recorded up to 17 Ebola cases in a new outbreak of the deadly virus in the western province of Equateur, and 11 of those infected have died, medical authorities said on Monday. The authorities had reported 12 infections last week in the central African country, whose dilapidated health system is also combating a measles epidemic that has killed over 6,000 people and COVID-19, which has infected over 4,800 and killed 112.

Chinese capital reinstates curbs as coronavirus resurfaces

Several districts of the Chinese capital put up security checkpoints, closed schools and ordered people to be tested for the coronavirus on Monday after an unexpected spike of cases linked to the biggest wholesale food market in Asia. After nearly two months with no new infections, Beijing officials have reported 79 cases over the past four days, the city's biggest cluster of infections since February.

Russia's coronavirus death toll passes 7,000

Russia on Monday reported 8,246 new cases of the coronavirus, taking the nationwide tally of infections to 537,210, the country's coronavirus crisis response centre said. It said 143 people had died from the virus in the past 24 hours, taking Russia's overall death toll to 7,091.

Crowds gather for coronavirus tests in Beijing amid new outbreak

On a sweltering Beijing afternoon, police vehicles blocked roads near the Guangan Sports Center complex and security guards warned the public to stay clear as residents filed in for testing amid the city's COVID-19 outbreak. Staff in white PPE suits with megaphones yelled directions from gates, telling the crowds to gather in groups according to neighbourhood and avoid touching each other.

Germany's confirmed coronavirus cases rise by 192 to 186,461 - RKI

The number of confirmed coronavirus cases in Germany increased by 192 to 186,461, data from the Robert Koch Institute (RKI) for infectious diseases showed on Monday. The reported death toll rose by four to 8,791, the tally showed.

Mutation in new coronavirus increases chance of infection: study

A specific mutation in the new coronavirus can significantly increase its ability to infect cells, according to a study by U.S. researchers. The research may explain why early outbreaks in some parts of the world did not end up overwhelming health systems as much as other outbreaks in New York and Italy, according to experts at Scripps Research.

France expects AstraZeneca COVID-19 vaccine to be shared pro rata

A deal between AstraZeneca and France over potential COVID-19 vaccines involves doses being split between countries on a pro-rata basis based on population, a source at the French President's office said on Monday. The British drugmaker signed a contract with European governments at the weekend to supply the region with up to 400 million doses of its potential vaccine.

Here is the original post:
Health News Roundup: Trial of rheumatoid arthritis drug in COVID-19 patients; new Ebola outbreak in Congo and more - Devdiscourse

Read More...

Rheumatoid Arthritis Diagnostic Device Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of…

Tuesday, June 16th, 2020

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis Diagnostic Device Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis Diagnostic Device, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=170432&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis Diagnostic Device manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis Diagnostic Device Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis Diagnostic Device market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis Diagnostic Device market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis Diagnostic Device Market, By Product

Rheumatoid Arthritis Diagnostic Device Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=170432&utm_source=COD&utm_medium=888

Rheumatoid Arthritis Diagnostic Device Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis Diagnostic Device market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis Diagnostic Device Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis Diagnostic Device Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis Diagnostic Device Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis Diagnostic Device Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis Diagnostic Device Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis Diagnostic Device Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis Diagnostic Device Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=170432&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Airport Surveillance Radar Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

AR and VR Smart Glasses Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Business Accounting Software Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the article here:
Rheumatoid Arthritis Diagnostic Device Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of...

Read More...

Rheumatoid Arthritis Therapeutics Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Tuesday, June 16th, 2020

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis Therapeutics Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis Therapeutics, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=190289&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis Therapeutics manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis Therapeutics Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis Therapeutics market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis Therapeutics Market, By Product

Rheumatoid Arthritis Therapeutics Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=190289&utm_source=COD&utm_medium=888

Rheumatoid Arthritis Therapeutics Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis Therapeutics market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis Therapeutics Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis Therapeutics Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis Therapeutics Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis Therapeutics Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis Therapeutics Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis Therapeutics Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis Therapeutics Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=190289&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Cannabis Extract Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cocoa Butter Equivalent (CBE) Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Collagen Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Rheumatoid Arthritis Therapeutics Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Read More...

Psoriatic Arthritis Treatment Market Scope Emerging Trends, Analysis and Forecast 2028 – Medic Insider

Tuesday, June 16th, 2020

Global Psoriatic Arthritis Treatment Market: Overview

The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called psoriases start to exhibit extreme symptoms of arthritis. This results in excessive pain, uneasiness, and discomfort for the sufferer, often necessitating emergency dosage of steroids. Hence, there is a dire need to ensure that psoriatic arthritis is controlled which in turn gives an impetus to the growth of the global market. The revenue scale of the global psoriatic arthritis treatment market shall improve alongside advancements in the field of geriatric care.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5495

There is no permanent treatment for psoriatic arthritis, and it can only be controlled with proper medication. The discomfort suffered by people affected with psoriatic arthritis is abysmal. Owing to the aforementioned factors, the global psoriatic arthritis treatment market is projected to attract the attention of the medical fraternity in the years to follow. The demand for psoriatic arthritis is projected to reach new heights in the years to follow.

The global psoriatic arthritis treatment market can be segmented on the basis of the following parameters: drug class, route of administration, and region. Based on drug class, the global psoriatic arthritis treatment market can be segmented into Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Antiinflammatory Drugs (NSAIDs), and biologics. Based on route of administration, the global psoriatic arthritis treatment market can be segmented into orals, topical, and injectables.

Global Psoriatic Arthritis Treatment Market: Notable Developments

Several advancement in the competitive landscape have become a key characteristic of the global psoriatic arthritis treatment market in recent times.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5495

Global Psoriatic Arthritis Treatment Market: Growth Driver

The occurrence of psoriatic arthritis is preceded by the severity of psoriasis in individuals. Hence, the field of dermatology needs to be work in conjunction with other medical departments in order to treat and control psoriatic arthritis. Hence, the global psoriatic arthritis treatment market shall expand alongside advancements in the field of dermatology. Furthermore, the availability of over-the-counter drugs for treatment of psoriatic arthritis propelled demand within the global market.

The joints suffer severe pain during psoriatic arthritis treatment, and the patients need to be quick recourse treatments. In a lot of cases, psoriatic arthritis poses a risk of permanent damage of joints. For this reason, the demand for psoriatic arthritis treatment has been rising at a stellar pace.

Global Psoriatic Arthritis Treatment Market: Regional Outlook

On the basis of geography, the global psoriatic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Asia Pacific. The psoriatic arthritis treatment market in North America is expanding alongside advancements in the field of regional healthcare.

The global psoriatic arthritis treatment market can be segmented as:

Route of Administration

Read Comprehensive Overview of Report @https://www.tmrresearch.com/psoriatic-arthritis-treatment-market

Link:
Psoriatic Arthritis Treatment Market Scope Emerging Trends, Analysis and Forecast 2028 - Medic Insider

Read More...

Psoriatic Arthritis Drugs Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Tuesday, June 16th, 2020

New Jersey, United States,- A detailed research study on Psoriatic Arthritis Drugs Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Psoriatic Arthritis Drugs, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=201953&utm_source=COD&utm_medium=888

Leading Psoriatic Arthritis Drugs manufacturers/companies operating at both regional and global levels:

Psoriatic Arthritis Drugs Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Psoriatic Arthritis Drugs market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Psoriatic Arthritis Drugs market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Psoriatic Arthritis Drugs Market, By Product

Psoriatic Arthritis Drugs Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201953&utm_source=COD&utm_medium=888

Psoriatic Arthritis Drugs Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Psoriatic Arthritis Drugs market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Psoriatic Arthritis Drugs Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Psoriatic Arthritis Drugs Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Psoriatic Arthritis Drugs Market, By Deployment Model

5.1 Overview

6 Psoriatic Arthritis Drugs Market, By Solution

6.1 Overview

7 Psoriatic Arthritis Drugs Market, By Vertical

7.1 Overview

8 Psoriatic Arthritis Drugs Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Psoriatic Arthritis Drugs Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=201953&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Engineered Fluids Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Seam Tapes Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Interventional Oncology Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Psoriatic Arthritis Drugs Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Read More...

Fact check: A mix of honey and cinnamon may have some health benefits, more studies needed – USA TODAY

Tuesday, June 16th, 2020

Scientists have long suspected that cinnamon can help prevent blood-sugar spikes and protect against insulin resistance, a risk factor for diabetes. But how, exactly, has remained a mystery.

In a Facebook post, a bottle of golden-colored honey and red-brown cinnamon is held side-by-side. The accompanying text alludes to a treatment drug companies wont like getting around.

It is found that a mix of honey and cinnamon cures most diseases, David Wright posted to Facebookin 2014 in a post that has garnered attention on the platform since late May. In separate paragraphs dedicated to certain diseases and common ailments, heprovides detailed dosages and methods for intake.

Make a paste of honey and cinnamon powder, put it on toast instead of jelly and jam, and eat it regularly for breakfast, Wright advises for heart disease. For arthritis, bladder infections, colds, GI and respiratory issues, longevity and even hearing loss, he recommends mixing varying proportions of the household spice and sweetener with boiling or lukewarm water to drink daily or until symptoms dissipate.

Wrightalso dispenses relevant scientific facts to add a layer of medical authenticity.

A scientist in Spain has proved that honey contains a natural Ingredient which kills the influenza germs and saves the patient from flu, he writes. Constant use of honey strengthens the white blood corpuscles (where DNA is contained) to fight bacterial and viral diseases.

The post has received over a million shares and 70,000 comments, the latter of which have been overwhelmingly positive.

Wow, I knew it helped with some things but I had no idea it helped so many things! Belinda Lee Christian commented.

Some commenters, however, expressed skepticism.

How the heck is hearing related to something you ingest?? Diane Plourde asked.

Wright did not respond to USA TODAY for commentsand clarification.

The use of honey has been well-documented since antiquity, dating as far back as the Stone Age. In the fourth century B.C., the Sumeriansof Mesopotamia, a region once spanning most of modern-day Iraq and eastern Syria, documented the sweet, viscous syrup as both nutritional and medical, even usingit as an ointment. Ancient texts penned by the fathers of early medicine like Aristotle and Hippocrates, as well as Arab and Ayurvedic doctors, also recognized honeys medicinal benefits.

In the last 20 years or so, scientists have uncovered much about this food made by the humble bee.

Bees collect the dilute-sugary nectar of flora plants, produce an enzymatic activity after ingestion, regurgitate it into honey cells and evaporate a high percentage of water out of it, Dana Hunnes, a senior dietitian at Ronald Reagan UCLA Medical Center, explained to Timelast year.

The end product honey consists of simple sugar molecules, mostly fructose and glucose, which can be easilyused by the body for energy.

The rest of honeys chemical composition is made up of enzymes, amino acids, vitamins, calcium, iron, zinc and potassium to name a few. And much of its prized pharmacological effect comes from antioxidants called polyphenols.

These compounds are responsible for some of honeys potential health benefits and part of what distinguishes the sweetener from more traditional ones like sugar, Jenny Friedman, a Philadelphia-based registered dietitian, told Time last year.

Cinnamon, like honey, has also enjoyed a long history. Its first documented use was as a perfuming agent during the ancient Egyptian embalming process. During the Middle Ages, it became known as a useful meat preservativeand a treatment for coughs, arthritis and sore throats.

The much-loved fragrant spice, obtained from the bark of Lauraceae family of trees found in Asia, Australia and South America, contains polyphenols and various other chemical compounds with reported anti-inflammatory, antimicrobial, antidiabetic, anticancer and lipid-lowering properties.

According to the U.S. Department of Agriculture, one teaspoon of ground cinnamon contains 26 mg of calcium, 0.2 mg of iron, less than 1 mg of magnesium and phosphorous each, about 11 mg of potassium and 0.4 micrograms of vitamin A.

More: Best recipes for stress baking during the pandemic, from beginner level to challenging

Many studies involving honey or cinnamon have not focused on their combined action. Thanks to its antimicrobial properties, honey has shown promise in wound care and fighting off catheter-associated UTIs. More rigorous studies are needed to conclude it's helpfulness in alleviating eczema, ringworm or acne but its generally agreed salving on some of the natural sweetenerdoesnt hurt.

Studies have found cinnamon could potentially lower fasting blood glucose and blood pressure in type 2 diabetics. Levels of LDL, total cholesterol and HDL may also improve but are subject to further study. Additionally, cinnamon may protect against stomach ulcers, Alzheimers disease, increase life span, prevent hepatitis C viral entry and improve arthritic pain. Most results are derived from animal models, in vitro studies or from small sample sizes and would require detailed investigation.

The claim of honey and cinnamon for oral hygiene, however, may be substantiated. One 2017 study found that honey and cinnamon appear to work together to fight against Streptococcus mutans, a bacterium known for its role in tooth decay.

There are no studies indicating honey and cinnamon effective in curing hearing loss, fatigue or increasing life span in human subjects. While honey and cinnamon may soothe symptoms of the common cold or the flu, they cannot kill influenza germs (influenza being a virus and not a bacteria) as the Facebook post claims.

There are hundreds of honey types worldwide, with over 300 variations in the United States alone. The benefits of one particular honey can differ from another depending on many factors including the nectars floral source, the environment and even the bees age. New Zealand manuka honey has been well-researched and recognized for its medicinal properties; Tualang honey found in Malaysia and buckwheat honey are also gaining attention. Buyers must beware of imported honey, which can be filtered with other sweeteners like corn syrup thereby reducing its health and nutritional value.

When it comes to cinnamon, it may come as a surprise to learn most supermarket cinnamon is not of the true cinnamon, or Ceylon variety, but cassia, Chinese cinnamon. While both have been used in studies looking at effects on blood glucose, eating too much of cassia cinnamon may be harmful in large doses.

As far as recommended daily dosages of either one, experts recommend consuming no more than a tablespoon of honey or one-quarterto about 1.25 teaspoonsof cassia daily (there are no human studies available yet for optimal dosing with Ceylon cinnamon). Many of the doses prescribed in the Facebook post exceed the recommended limits.

We rate the health claim of honey and cinnamon as a cure for most diseases PARTLY FALSE because some of it was not supported by our research. While its true honey and cinnamon individually may help improve and even protect against some diseases, there is a lack of studies looking at both honey and cinnamon together. There's no scientific evidence backing improving hearing loss and the claim of weight loss may be inferred but has not been confirmed. The prescribed dosages mentioned exceed the recommended daily servings and could be potentially harmful.

Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.

Our fact check work is supported in part by a grant from Facebook.

Read or Share this story: https://www.usatoday.com/story/news/factcheck/2020/06/14/fact-check-health-benefits-honey-and-cinnamon/3175131001/

More here:
Fact check: A mix of honey and cinnamon may have some health benefits, more studies needed - USA TODAY

Read More...

Less Than One Year Post Launch, AbbVie’s Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings -…

Thursday, June 4th, 2020

EXTON, Pa., June 4, 2020 /PRNewswire/ --The latest quarterly report included in Spherix's RealTime Dynamix: Rheumatoid Arthritis (US)service captures the responses of 105 rheumatologists surveyed in May 2020 and highlights the shifting dynamics of the rheumatoid arthritis (RA) treatment landscape, driven largely by the recent approval of AbbVie's JAK inhibitor, Rinvoq, as well as the present impact of the COVID-19 pandemic on rheumatology practices. According to the survey results that are trended back to 2016, the RA treatment landscape continues to shift away from the legacy TNF inhibitors (i.e., AbbVie's Humira and Amgen's Enbrel) which have long been the gold standard, while alternate mechanism of action (MOA) agents have remained relatively stable in both user base and brand share with the exception of the newest market entrant, Rinvoq.

Perhaps the greatest impact of Rinvoq is being felt by Pfizer's Xeljanz. Approved in 2012, Xeljanz enjoyed the "only JAK inhibitor" status for six years until Eli Lilly's Olumiant was approved. Where Olumiant faced challenges with regulatory delays and ultimately a less than desirable product label, Rinvoq came out of the gates strong. In only nine months on the market, the majority of rheumatologists now select Rinvoq as their JAK of choice if limited to just one for the treatment of RA. Indeed, rheumatologists report that more than one in five of their JAK-treated RA patients are currently prescribed Rinvoq, and six-month projections call for this figure to double. AbbVie's SELECT-COMPARE trial, demonstrating Rinvoq's superiority over Humira, appears to be giving Rinvoq an advantage over existing JAK inhibitors, Xeljanz and Olumiant.

While the clinical data for Rinvoq is strong, the "AbbVie Effect" is also in full force; rheumatologists (in addition to dermatologists and gastroenterologists) consistently rate AbbVie as the strongest industry partner. AbbVie representatives are in active promotion mode, with current reports of virtual detailing during the COVID-19 crisis, often providing samples which are helping to generate new patient starts and to bridge patients through the prior authorization process. In addition, rheumatologists report the recently debuted direct to consumer marketing campaign is driving increased patient requests for the brand, a majority of which result in a prescription.

Though rheumatologists seem to favor Rinvoq of late, they are also likely to prescribe a second and even a third JAK agent if the first JAK fails, a behavior that mimics the traditional treatment pattern of TNF-cycling. In fact, JAK-cycling has increased significantly versus a year ago, with the availability of the third option (Rinvoq) now available. Despite increased use of the class, rheumatologists remain unsure as to which JAK pathway they believe to be the most efficacious and the safest treatment of RA, despite messaging efforts by manufacturers to attempt differentiation on this front.

Rinvoq may soon have to share the spotlight with another JAK, Gilead's filgotinib, which has the greatest unaided and aided awareness of all pipeline assets tested. Filgotinib, the next likely agent to launch in RA, is also selected by almost one-half of surveyed rheumatologists as the "favorite" agent among pipeline assets and is the only agent respondents predict will have a presence in the first-line setting soon after launch. Positive perceptions surrounding Gilead's pipeline agent are perhaps (at least somewhat) a byproduct of the increased positive publicity the company has received associated with the approval of remdesivir as a COVID-19 treatment. Filgotinib also stands the possibility of bringing to the table an improved safety profile over existing JAKs, but the degree to which this positively impacts FDA labeling is yet to be seen.

Other agents with novel MOAs, including EMD Serono's BTK inhibitor, evobrutinib and GSK's anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF) monoclonal antibody, otilimab, are also generating early positive mentions. Indeed, this rich pipeline is poised to continue transforming the advanced systemic treatment landscape over the coming years.

About RealTime DynamixRealTime Dynamix: Rheumatoid Arthritis (US) is an independent service providing strategic guidance through rapid and comprehensive quarterly reports, which include market trending since 2016, launch tracking, and a fresh infusion of unique content with each wave.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Kristen Henn, Business Development ManagerEmail:[emailprotected]www.spherixglobalinsights.com

SOURCE Spherix Global Insights

Spherix Global Insights

Continued here:
Less Than One Year Post Launch, AbbVie's Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings -...

Read More...

Treating COVID-19 or Rheumatoid Arthritis? Exploring Proposed Drug Therapy, Safety Concerns – Pharmacy Times

Thursday, June 4th, 2020

Treating COVID-19 or Rheumatoid Arthritis? Exploring Proposed Drug Therapy, Safety Concerns

Jessica Mattingly, PharmD Candidate, Amy Priest, PharmD Candidate, and Emily Frederick, PharmD

COVID-19 is transmitted through respiratory droplets. In severe cases, the virus can wreak havoc on the lungs and may lead to the development of pneumonia or the potentially fatal condition acute respiratory distress syndrome.2 Consequently, due to the toll the disease takes on the body, some patients are left unable to fight the infection. Upon discovering the effects on the lung, researchers determined the infection that leads to COVID-19 to be severe acute respiratory syndrome-related coronavirus (SARS-COV-2).2

This viral infection in the lungs leads to the excessive production of cytokines, causing a phenomenon known as a cytokine storm. This storm begins with the release of interleukin-1 (IL-1), along with other cytokines, within minutes to hours of infection. The immune system is then further stimulated by interleukin-6 (IL-6) as it attempts to eradicate the infection.

Finally, interleukin-10 (IL-10) production is stimulated to tone down the immune response. However, at this stage, the cytokine storm has already damaged the lung tissue and must be repaired in order to help eradicate the infection.

The damage is repaired by producing new collagen tissue. Meanwhile, the infection may still be worsening throughout the body and potentiating further complications, sepsis, and possible mortality.3 With the potentially severe consequences of COVID-19 infection, it is vital to identify treatment options that are effective while minimizing harm from potential adverse drug reactions.

As scientists fervently research treatments, one avenue of exploration has been repurposing existing drugs as COVID-19 treatments. Examples of repurposed drugs are those commonly indicated for autoimmune diseases such as rheumatoid arthritis (RA). However, what characteristics of RA treatments possibly connect to COVID-19 treatment?

RA is an autoimmune disease wherein treatments are targeted to suppress the immune system to preserve functional use and reduce pain in patients with the disease. The mainstays of therapy include drugs that inhibit the immune system mainly through actions on cytokines and T-cells. However, some drugs commonly used to treat RA can also be utilized in other conditions.

For example, hydroxychloroquine, which reduces cytokine production is also used for malaria prophylaxis but relies on a different mechanism of action for this purpose. Although hydroxychloroquine was granted EUA for treating COVID-191 in March 2020, some studies have found cause for safety concerns, including increased risk of death.4 Studies are ongoing to to determine the efficacy and safety of the drug for COVID-19. In RA treatment, hydroxychloroquines efficacy may be at least in part secondary its effects on cytokine production. Furthermore, for COVID-19, hydroxychloroquine may inhibit the virus ability to bind/penetrate respiratory cells.5

Many other drugs that also treat autoimmune diseases (including RA agents) have been proposed but require more clinical data.6,7

When considering these drugs as possible COVID-19 treatments, the safety and common adverse effects of these proposed medications should be considered and weighed carefully (Table). At the time of publication, only hydroxychloroquine and remdesivir (which is not indicated for RA) had compassionate use status. This use brings an enhanced focus on drug safety profiles to light.

Perhaps the most concerning safety issue associated with hydroxychloroquine treatment is potential cardiac toxicity, specifically with noted changes in ECG readings leading to some patients discontinuing drug therapy.8 Another noted safety concern is retinal toxicity.

This effect can occur with both acute and long-term use but is rare in the acute phase (<1%). The risk of retinal toxicity, however, is increased in doses above 5 mg/kg of actual body weight daily or with extended therapies. Consequently, ocular examinations are recommended prior to initiation of chronic therapy but may not be meaningful or feasible for COVID-19 patients requiring swift intervention.9

Table 1: Summary of RA Agents Proposed as COVID-19 Treatments Potential COVID-19 Therapy

For SARS-CoV-19 on the other hand, hydroxychloroquines potentially effective actions include binding to Salic acid residues and gangliosides. This action prevents the virus from attaching to these sites and getting into the cell in order to replicate.3

The other medications listed in the table (excluding corticosteroids) block a specific aspect of interleukins, which are other immune system regulators like cytokines. Tocilizumab and sarilumab are both IL-6 inhibitors while anakinra is an IL-1 inhibitor.

These affect the immune process at a certain location without blocking the entire immune system and help limit the cytokine storm. Tocilizumab has an indication for the treatment of cytokine release syndrome due to chimeric antigen receptor-T cell therapy in severe or life-threatening cases. Meanwhile corticosteroids inhibit inflammatory mediators.

In summary, although each medication exerts its effects differently, they all work in some way to inhibit a portion of the immune response that could present a risk of secondary infections in those with already taxed immune systems, such as COVID-19 patients.10-15

Upon inspection of the medications considered to potentially treat COVID-19, common goals seem to be a reduction in cytokine storm by either inhibiting interleukins in the storm itself or inhibiting the entry of the virus into cells. With the decrease in the cytokine storm comes the reduction of the damage done to the lungs by the immune system and possibly decreased clinical worsening, sepsis, and ultimate mortality.

Continued research is drastically needed in this area to gain insight on an effective strategy to combat COVID-19. Providers must also continue to consider potential safety repercussions of treatment options, particularly the safety of proposed immunosuppressive agents.

REFERENCES

Continue reading here:
Treating COVID-19 or Rheumatoid Arthritis? Exploring Proposed Drug Therapy, Safety Concerns - Pharmacy Times

Read More...

Arthritis treatment: The topical gel shown to ease joint pain by nearly fifty percent – Express

Thursday, June 4th, 2020

According to the NHS, the severity of osteoarthritis symptoms can vary greatly from person to person, and between different affected joints.

"For some people, the symptoms can be mild and may come and go. Other people can experience more continuous and severe problems which make it difficult to carry out everyday activities," explains the health body.

Unfortunately, there's no cure for osteoarthritis, but the condition does not necessarily get any worse over time.

Simple lifestyle tweaks can greatly alleviate joint complaints and help you maintain quality of life.

READ MORE:Paddy McGuinness health: Top Gear host explains condition that leaves him 'knackered'

They found that in five trials, daily administration of capsaicin gel was significantly more effective for pain reduction than placebo.

In the study that spanned over a period of 12-weeks, there was over a 50 percent reduction in pain with capsaicin gel use.

According to the Arthritis Foundation (AF), applied as a topical cream, gel or patch, capsaicin activates specific nerve receptors causing local heat, stinging and/or itching sensations.

"Prolonged activation of these receptors causes them to lose their ability to function properly (and process pain signals) for extended periods of time," explains the AF.

It is worth noting that capsaicin must be used regularly to keep the nerve receptors from working properly and processing pain signals, it adds.

Exercise is one of the most important treatments for people with osteoarthritis, whatever your age or level of fitness.

As the NHS points out, exercise may seem counterintuitive if you are suffering from osteoarthritis pain and stiffness, but the reverse is true.

"Regular exercise that keeps you active, builds up muscle and strengthens the joints usually helps to improve symptoms," says the health body.

Exercise is also good for losing weight, improving your posture and relieving stress, all of which will ease symptoms, notes the health site.

One of the most effective exercises for controlling weight is aerobic exercise.

"Aerobic exercise also reduces fatigue and builds stamina, while helping control weight by increasing the number of calories the body uses," explains the AF.

Examples of this type of exercise includes walking, jogging, bicycling, swimming or using the elliptical machine.

View post:
Arthritis treatment: The topical gel shown to ease joint pain by nearly fifty percent - Express

Read More...

Rheumatoid Arthritis and Cardiovascular Disease Share Etiology – Rheumatology Network

Thursday, June 4th, 2020

Researchers writing in Arthritis and Rheumatology report that high levels of anti-citrullinated protein antibodies (anti-CCP2) appear to be markers for future cardiovascular events in rheumatoid arthritis patients.

The study is based on an analysis of 2,814 rheumatoid arthritis patients who, over the course of 13 years, experienced 375 cardiovascular-related incidents, including acute coronary syndrome, stroke and cardiovascular-related deaths.

It is known that rheumatoid arthritis patients are at increased risk of cardiovascular disease due to a combination of traditional risk factors and, perhaps a shared etiology between rheumatoid arthritis and cardiovascular disease, wrote the authors who were led by Helga Westerlind, Ph.D., of the Karolinska Institute in Sweden. Previously, she and other researchers have reported that a correlation exists between accrued rheumatoid arthritis disease activity and high levels of anti-citrullinated protein antibodies (ACPA) and an increased risk of acute coronary syndromes, such as stroke, cardiovascular mortality, which was confirmed in this study.

In the new study, Dr. Westerlind and colleagues examined the presence and levels of anti-CCP2, specific ACPAs and their combinations, rheumatoid factor isotypes, and risk for acute coronary syndrome, stroke and cardiovascular-related death in this group of rheumatoid arthritis patients.

They found that elevated levels of anti-CCP2 were associated with acute coronary syndrome (1.46 hazard ratio (95% confidence interval), stroke (1.47 HR), cardiovascular-related death (P value 0.024) and major adverse cardiovascular events (MACE) (1.34 HR). Associations were also documented for the number of ACPA sub-specificities; IgM rheumatoid factor with all cardiovascular endpoints except for acute coronary syndrome; and, IgA rheumatoid factor was found to be exclusively associated with cardiovascular disease-related death.

From a clinical perspective, our data implies that patients with seronegative RA are at a lower risk of CV events, while patients with high anti-CCP2 levels or presence of IgA or IgG RF at diagnosis are at higher risk and might benefit from closer monitoring from a cardio preventative perspective. In this regard, specific ACPA sub-specificities offer no further predictive capacity.

To conclude, in patients with RA, ACPA and rheumatoid factor are linked to risks for several types of CV endpoints, and to CV and overall mortality, independently of smoking. These associations do not seem to be driven by any specific (pattern of) ACPAs, suggesting that for CV co-morbidity in RA, autoAb load may be more important than individual ACPAs. For RF the CV risks seem to vary across RF isotypes, the authors wrote.

REFERENCE

Helga Westerlind, Johan Rnnelid, Monika Hansson, Lars Alfredsson, et al. "Anticitrullinated protein antibody specificities, rheumatoid factor isotypes and incident cardiovascular events in patients with rheumatoid arthritis," Arthritis and Rheumatology.First published:31 May 2020 https://doi.org/10.1002/art.41381

Read the original post:
Rheumatoid Arthritis and Cardiovascular Disease Share Etiology - Rheumatology Network

Read More...

Quiz: Best Practices for Corticosteroid Use in Active Rheumatoid Arthritis – Rheumatology Network

Thursday, June 4th, 2020

Glucocorticoids are the most frequently used class of drugs for rheumatoid arthritis (RA) because they are effective at relieving symptoms, and widely available at low cost. While this drug class has clear benefits for rheumatoid arthritis, it comes at a price in terms of a wide array of potential side-effects. Test your knowledge on the use of corticosteroids in rheumatoid arthritis with this quiz.

Which of the following statements align with the 2015 American College of Rheumatology guidelines regarding the use of corticosteroids in patients with rheumatoid arthritis?

a) For the treatment of early rheumatoid consider add low-dose glucocorticoids (10 mg/day of prednisone or equivalent) in patients with moderate or high disease activity when starting disease-modifying antirheumatic drugs (DMARDs) or where DMARD or biologics have failed to control disease activity.

b) Short courses of low dose corticosteroids (10 mg/day of prednisone or equivalent) may be used first line in patients with early RA with only mild symptoms.

c) Consider using short-term glucocorticoids (up to 3 months) for disease flares.

d) For patients with advanced disease higher doses of corticosteroids may be needed to control flares

e) The risk/benet ratio of glucocorticoid therapy is unfavorable for most patients with rheumatoid arthritis

f) Glucocorticoids should be used at the lowest possible dose and for the shortest possible duration

g) The target should ideally be low disease activity or remission.

See the next page for the answer.

Follow this link:
Quiz: Best Practices for Corticosteroid Use in Active Rheumatoid Arthritis - Rheumatology Network

Read More...

Page 20«..10..19202122..3040..»


2022 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick